La Habana, Cuba

Danay Saavedra Hernández

This inventor holds 1 USPTO granted patent and 3 published patent applications. Top assignees: Centro De Inmunologia Molecular, Innovative Immunotherapy Alliance, S.A.. Active years: 2026.

USPTO Granted Patents = 1 

% Patents Active = 100.0

Average Co-Inventor Count = 13.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Danay Saavedra Hernández: Innovator in Therapeutic Compositions

Introduction

Danay Saavedra Hernández is a notable inventor based in La Habana, Cuba. He has made significant contributions to the field of therapeutic compositions, particularly in the treatment of tumors of epithelial origin. His innovative work has led to the development of a patent that addresses critical health challenges.

Latest Patents

Danay holds a patent titled "Use of Therapeutic Compositions for the Treatment of Patients with Tumors of Epithelial Origin." This patent represents a significant advancement in cancer treatment, showcasing his dedication to improving patient outcomes. He has 1 patent to his name, reflecting his commitment to innovation in medical science.

Career Highlights

Throughout his career, Danay has worked with prominent organizations that focus on immunotherapy and molecular biology. He has been associated with Innovative Immunotherapy Alliance, S.A. and Centro de Inmunología Molecular. These experiences have enriched his expertise and allowed him to contribute meaningfully to the field of therapeutic research.

Collaborations

Danay has collaborated with Tania Crombet Ramos, a fellow innovator in the field. Their partnership has likely fostered advancements in therapeutic strategies and research methodologies.

Conclusion

Danay Saavedra Hernández exemplifies the spirit of innovation in the medical field through his patent and collaborative efforts. His work continues to inspire advancements in cancer treatment and therapeutic compositions.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…